Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide versus Rasasinex for allergic rhinitis symptom control
IRCT20110614006804N2Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in allergic rhinitis (AR) (2 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Nasal congestion symptoms, Sleep disorder and 3 more. Started Dec 2020; status: completed.
02
Drugs
budesonide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on IRCT20110614006804N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110614006804N2.